Logo

Luminex Licenses miRNA IP from MIT to Develop and Sell Assays

Feb 28, 2006

NEW YORK, Feb. 28 (GenomeWeb News) - Luminex has taken a non-exclusive license from the Massachusetts Institute of Technology to develop and commercialize miRNA assays.

 

The deal applies to intellectual property developed by MIT, Howard Hughes Medical Institute, Dana-Farber Cancer Institute, and other members of the Broad Institute.

 

Additional details were not released.

Breaking News
The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.